A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 29
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PD-L1
Long Form : protein ligand 1
No. Year Title Co-occurring Abbreviation
2020 Activating Antibodies to Calcium-Sensing Receptor In Immunotherapy-Induced Hypoparathyroidism. CaSR, CTLA-4, ICIs, irAEs
2020 PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. 18FDG, CTLA-4, irAEs, PET, TPO
2019 HIF1alpha/PD-L1 axis mediates hypoxia-induced cell apoptosis and tumor progression in follicular thyroid carcinoma. FTC, HIF-1alpha
2019 Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome. AD, T1DM
2019 Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. ---
2019 Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma. MCC
2019 Inhibition of programmed cell death protein ligand-1 (PD-L1) by benzyl ether derivatives: analyses of conformational change, molecular recognition and binding free energy. ---
2019 Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment. ---
2019 New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. EGFR, IHC, MTV, NLR, NSCLC, OS, PFS, PLR, TAMs, TLG
10  2019 PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. ICIs, NSCLC
11  2019 PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth. ---
12  2019 T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. IHC, NSCLC, OS, RFS, TILs, TIM-3
13  2019 [Basis of Tumor Microenvironment Relevant to Immunotherapies for Brain Metastases of NSCLC]. BM, NSCLC
14  2019 [Immunotherapy in Epidermal Growth Factor Receptor-mutant 
Non-small Cell Lung Cancer]. EGFR, NSCLC
15  2018 Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. anti-CTLA4, DI, irAEs
16  2018 Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. HNSCC
17  2018 Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. CTLA-4
18  2018 Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy. CD, i.t, TLR9
19  2018 PD-1 Blockade for Improving the Antitumor Efficiency of Polymer-Doxorubicin Nanoprodrug. DOX, HA
20  2018 Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome. AUC, EBV, ENKTL
21  2018 Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. NSCLC, SCC
22  2018 Small cell lung cancer and immuno-oncologic agents: End of the cisplatin-etoposide era? NSCLC, SCLC
23  2017 Cardiovascular Complications Associated With Novel Cancer Immunotherapies. CTLA-4
24  2017 COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. 15-PGDH, mPGES1, PGE2
25  2017 Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. DFS, EBVaGC, IHC, LN, PD-L2
26  2017 Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. APC, mAb, NIR-PIT
27  2017 Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China. PD-1
28  2017 Strategies targeting angiogenesis in advanced non-small cell lung cancer. NSCLC, TKIs, VEGF
29  2017 Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. IHC, NSCLC